Akira Ohara

Summary

Country: Japan

Publications

  1. ncbi request reprint Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia
    Akira Ohara
    First Department of Pediatrics, Toho University School of Medicine, Tokyo, Japan
    Br J Haematol 116:151-4. 2002
  2. doi request reprint Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children
    Hiroshi Yagasaki
    Department of Pediatrics, School of Medicine, Nihon University, 30 1 Ohyaguchi Kamicho, Itabashi ku, 173 8610, Tokyo, Japan
    Ann Hematol 93:747-52. 2014
  3. doi request reprint No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15
    Motohiro Kato
    Department of Haematology Oncology, Saitama Children s Medical Centre, Saitama, Japan Department of Paediatrics, The University of Tokyo, Tokyo, Japan
    Br J Haematol 164:376-83. 2014
  4. doi request reprint Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group
    Daisuke Tomizawa
    Division of Leukemia and Lymphoma, Children s Cancer Center, National Center for Child Health and Development, 2 10 1 Okura, Setagaya Ku, Tokyo, 157 8535, Japan
    Int J Hematol 102:602-10. 2015
  5. doi request reprint Outcome of pediatric acute lymphoblastic leukemia with very late relapse: a retrospective analysis by the Tokyo Children's Cancer Study Group (TCCSG)
    Motohiro Kato
    Department of Pediatrics, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Int J Hematol 101:52-7. 2015
  6. doi request reprint Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children's Cancer Study Group (TCCSG) clinical trials
    Motohiro Kato
    Department of Pediatrics, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Int J Hematol 100:180-7. 2014
  7. doi request reprint The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study
    Daisuke Hasegawa
    Department of Pediatrics, St Luke s International Hospital, Tokyo, Japan
    Pediatr Blood Cancer 58:23-30. 2012
  8. doi request reprint Erythrocyte glutathione is a novel biomarker of Diamond-Blackfan anemia
    Taiju Utsugisawa
    Department of Transfusion Medicine and Cell Processing, Tokyo Women s Medical University, Tokyo, Japan
    Blood Cells Mol Dis 59:31-6. 2016
  9. doi request reprint Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99)
    Daisuke Hasegawa
    Department of Pediatrics, St Luke s International Hospital, Tokyo, Japan
    Pediatr Blood Cancer 53:1011-5. 2009
  10. ncbi request reprint Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis
    Shouichi Ohga
    Aplastic Anaemia Committee of the Japanese Society of Paediatric Haematology, Tokyo, Japan
    Br J Haematol 118:313-9. 2002

Collaborators

  • Seiji Kojima
  • Atsushi Manabe
  • Masami Inoue
  • Motohiro Kato
  • Hitoshi Kanno
  • Hiroyuki Takahashi
  • Daisuke Tomizawa
  • Yoko Kato
  • Akiko M Saito
  • Kazunari Yamaguchi
  • Toshiyuki Kitoh
  • Tomohiro Morio
  • Jun Okamura
  • S Ohga
  • Akira Morimoto
  • Hiroaki Goto
  • Kazuko Kudo
  • Nobuyuki Yoshida
  • Masahiro Tsuchida
  • Hiroshi Yagasaki
  • Ryoji Kobayashi
  • Hiromasa Yabe
  • Yoshiyuki Kosaka
  • Taiju Utsugisawa
  • Ichiro Tsukimoto
  • Isao Hamaguchi
  • Tsutomu Toki
  • Yasushi Ishida
  • Etsuro Ito
  • Madoka Kuramitsu
  • Miho Maeda
  • Masahito Tsurusawa
  • Tatsutoshi Nakahata
  • Yuko Osugi
  • Hideo Mugishima
  • Takashi Kaneko
  • Junichi Hara
  • Eiichi Ishii
  • Shunji Igarashi
  • Toshitaka Uchiyama
  • Akira Ishiguro
  • Takako Aoki
  • Hiromi Ogura
  • Shoko Goto
  • Yoshitoshi Ohtsuka
  • Kazuko Hamamoto
  • Eizaburo Ishii
  • Mika Tokuyama
  • Chikako Kiyotani
  • Yuki Aoki
  • Masami Inoue
  • Naoya Nakadate
  • Kenichi Sugita
  • Yoshiyuki Takahashi
  • Sachi Sakaguchi
  • Kevin Y Urayama
  • Hiroyuki Shimada
  • Hideki Muramatsu
  • Hiroyuki Shichino
  • Runan Wang
  • Michio Ozeki
  • Takuo Mizukami
  • Kazuya Takizawa
  • Masatoshi Takagi
  • Atsuko Masumi
  • Tadashi Matsubayashi
  • Kumiko Goi
  • Nobuo Mizue
  • Kiminori Terui
  • Aiko Sato-Otsubo
  • Haruka Momose
  • Seishi Ogawa
  • Fumio Bessho
  • Yoshitoshi Otsuka
  • Kimihiko Sano
  • Hiroshi Ayukawa
  • Naoyuki Katano
  • Tsuyoshi Ito
  • Takashi Taga
  • Takeyuki Sato
  • Junichi Mimaya
  • Keiko Yumura-Yagi
  • Masahiro Sako
  • Masuji Yamamoto
  • Hisato Kigasawa
  • Megumi Oda
  • Tetsuya Takimoto
  • Takayuki Okamura
  • Nobuhiro Suzuki
  • Atsushi Ogawa

Detail Information

Publications19

  1. ncbi request reprint Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia
    Akira Ohara
    First Department of Pediatrics, Toho University School of Medicine, Tokyo, Japan
    Br J Haematol 116:151-4. 2002
    ..The incidence of MDS/AML in severe HAA patients who did not receive BMT (n = 30, 27.0 +/- 10.8%) appeared to be similar to that of severe idiopathic AA patients (n = 155, 14.7 +/- 3.7%) treated in the same period...
  2. doi request reprint Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children
    Hiroshi Yagasaki
    Department of Pediatrics, School of Medicine, Nihon University, 30 1 Ohyaguchi Kamicho, Itabashi ku, 173 8610, Tokyo, Japan
    Ann Hematol 93:747-52. 2014
    ..5, 95.8, and 96.8 %). These findings indicate that IST with ATG and CsA is justified as a first-line treatment for children with FAA who lack a human leukocyte antigen-matched sibling donor. ..
  3. doi request reprint No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15
    Motohiro Kato
    Department of Haematology Oncology, Saitama Children s Medical Centre, Saitama, Japan Department of Paediatrics, The University of Tokyo, Tokyo, Japan
    Br J Haematol 164:376-83. 2014
    ..In conclusion, experimental early intensification including high-dose cytarabine followed by L-asparaginase had no advantage over standard early intensification in paediatric IR ALL patients. ..
  4. doi request reprint Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group
    Daisuke Tomizawa
    Division of Leukemia and Lymphoma, Children s Cancer Center, National Center for Child Health and Development, 2 10 1 Okura, Setagaya Ku, Tokyo, 157 8535, Japan
    Int J Hematol 102:602-10. 2015
    ..However, considering the risk of acute and late toxicities associated with HSCT, its indication should be restricted...
  5. doi request reprint Outcome of pediatric acute lymphoblastic leukemia with very late relapse: a retrospective analysis by the Tokyo Children's Cancer Study Group (TCCSG)
    Motohiro Kato
    Department of Pediatrics, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Int J Hematol 101:52-7. 2015
    ..7 ± 7.1 %) was higher than that of very late relapse (15.5 ± 5.1 %, P = 0.03). The second relapse risk was low for very late relapse ALL, which suggests that these patients should be treated without allogeneic HSCT...
  6. doi request reprint Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children's Cancer Study Group (TCCSG) clinical trials
    Motohiro Kato
    Department of Pediatrics, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Int J Hematol 100:180-7. 2014
    ..In conclusion, our treatment strategy, which consists of intensive induction and block-type consolidation, provided improved outcomes for patients aged 15-18 years, comparable to those for patients aged 10-14 years...
  7. doi request reprint The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study
    Daisuke Hasegawa
    Department of Pediatrics, St Luke s International Hospital, Tokyo, Japan
    Pediatr Blood Cancer 58:23-30. 2012
    ..Based on the results from our previous study, we deferred the initial lumbar puncture until day 8 in remission induction therapy in order to reduce the frequency of cases with TLP+...
  8. doi request reprint Erythrocyte glutathione is a novel biomarker of Diamond-Blackfan anemia
    Taiju Utsugisawa
    Department of Transfusion Medicine and Cell Processing, Tokyo Women s Medical University, Tokyo, Japan
    Blood Cells Mol Dis 59:31-6. 2016
    ..Because extensive analysis of the RP genes failed to detect no causative mutation in approximately 40% of clinically diagnosed DBA patients, GSH may be useful an additional biomarker for diagnosis of DBA. ..
  9. doi request reprint Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99)
    Daisuke Hasegawa
    Department of Pediatrics, St Luke s International Hospital, Tokyo, Japan
    Pediatr Blood Cancer 53:1011-5. 2009
    ..Several reports have shown the efficacy of immunosuppressive therapy (IST) in adult patients with refractory anemia (RA), but its safety and efficacy remains to be fully elucidated in childhood RA...
  10. ncbi request reprint Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis
    Shouichi Ohga
    Aplastic Anaemia Committee of the Japanese Society of Paediatric Haematology, Tokyo, Japan
    Br J Haematol 118:313-9. 2002
    ..These results suggest that IST can be applied as the initial therapy for AA with cytogenetic abnormalities in the absence of completely matched donors...
  11. doi request reprint Secondary cancers among children with acute lymphoblastic leukaemia treated by the Tokyo Children's Cancer Study Group protocols: a retrospective cohort study
    Yasushi Ishida
    Department of Paediatrics, St Luke s International Hospital, Tokyo, Japan Centre of Clinical Epidemiology, St Luke s Life Science Institute, Tokyo, Japan
    Br J Haematol 164:101-12. 2014
    ..There was no evidence of a reduction in secondary cancer incidence despite marked decreases in cranial irradiation use in the recent protocols. ..
  12. doi request reprint Extensive gene deletions in Japanese patients with Diamond-Blackfan anemia
    Madoka Kuramitsu
    Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan
    Blood 119:2376-84. 2012
    ..Our data suggest that large deletions in RP genes comprise a sizable fraction of DBA patients in Japan. In addition, our novel approach may become a useful tool for screening gene copy numbers of known DBA genes...
  13. ncbi request reprint Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children
    Seiji Kojima
    Department of Developmental Pediatrics, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550, Japan
    Blood 100:786-90. 2002
    ..The present study suggests a close relationship between long-term use of G-CSF and secondary MDS in nonresponders to IST...
  14. ncbi request reprint Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings
    Ryoji Kobayashi
    Department of Paediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Br J Haematol 135:693-6. 2006
    ..7 +/- 6.2% vs. 87.9 +/- 8.0%, P = 0.044). These results suggest that BMT should be instituted immediately in children with severe AA who have human leucocyte antigen-identical siblings...
  15. ncbi request reprint Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia
    Yuko Osugi
    Dept of Pediatrics, Osaka General Medical Center, Osaka, Japan
    Haematologica 92:1687-90. 2007
    ..The probability of overall survival at 10 years was 88.3+/-4.9%, which supports the role of IST with ATG and CsA as treatment of choice for children with HAA without an HLA identical sibling donor...
  16. ncbi request reprint Features and outcome of neonatal leukemia in Japan: experience of the Japan infant leukemia study group
    Eiichi Ishii
    Department of Pediatrics, Saga University, Nabeshima, Saga, Japan
    Pediatr Blood Cancer 47:268-72. 2006
    ..We analyzed the features and outcome of neonatal leukemia in Japan to establish an appropriate treatment strategy for this rare disorder...
  17. ncbi request reprint No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol
    Shunji Igarashi
    Tokyo Children s Cancer Study Group, Department of Hematology and Epidemiology, National Center for Child Health and Development, Japan
    J Clin Oncol 23:6489-98. 2005
    ..To evaluate whether dexamethasone (DEXA) yields a better outcome than prednisolone (PRED) in a prospective, randomized, controlled trial for the treatment of childhood acute lymphoblastic leukemia (ALL)...
  18. ncbi request reprint Survival outcome after the first central nervous system relapse in children with acute lymphoblastic leukemia: a retrospective analysis of 79 patients in a joint program involving the experience of three Japanese study groups
    Masahito Tsurusawa
    Japanese Children s Cancer and Leukemia Study Group JCCLSG, Department of Pediatrics, Faculty of Medicine, Aichi Medical University, Aichi, Japan
    Int J Hematol 85:36-40. 2007
    ..7% +/- 5.8% (mean +/- SE) and 32.9% +/- 5.5%, respectively. The probability of remaining in second remission was significantly correlated with the leukocyte count (P= .005) and age (P= .02) at the initial diagnosis...
  19. ncbi request reprint Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia
    Yoshiyuki Kosaka
    Department of Pediatrics, Hyogo Children Hospital, Hyogo, Japan
    Blood 111:1054-9. 2008
    ..1%, SD) in the SCT group compared with 9.5% (+/- 9.0%) in the IST group (P = .001). These results suggest that SCT from an alternative donor offers a better chance of FFS than a second IST in patients not responding to an initial IST...